Milestone Pharmaceuticals Total Assets Growth & History (MIST)
Milestone Pharmaceuticals's total assets was $113.6M for fiscal 2025.
View full Milestone Pharmaceuticals company overviewMilestone Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $113.6M | $38.1M | +50.41% |
| 2024 | 2024-12-31 | $75.5M | $273,000 | +0.36% |
| 2023 | 2023-12-31 | $75.2M | $743,000 | +1.00% |
| 2022 | 2022-12-31 | $74.5M | −$45.4M | −37.85% |
| 2021 | 2021-12-31 | $119.8M | −$30.1M | −20.09% |
| 2020 | 2020-12-31 | $150.0M | $26.5M | +21.51% |
| 2019 | 2019-12-31 | $123.4M | $35.3M | +40.13% |
| 2018 | 2018-12-31 | $88.1M | — | — |
Milestone Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $181.6M | $134.2M | +283.04% |
| Q1 2026 | 2026-03-31 | $193.7M | $131.8M | +213.05% |
| Q4 2025 | 2025-12-31 | $113.6M | $38.1M | +50.41% |
| Q3 2025 | 2025-09-30 | $87.8M | $5.0M | +6.10% |
| Q2 2025 | 2025-06-30 | $47.4M | −$41.8M | −46.86% |
| Q1 2025 | 2025-03-31 | $61.9M | −$34.1M | −35.54% |
| Q4 2024 | 2024-12-31 | $75.5M | $273,000 | +0.36% |
| Q3 2024 | 2024-09-30 | $82.7M | −$4.4M | −5.06% |
| Q2 2024 | 2024-06-30 | $89.2M | −$7.8M | −8.03% |
| Q1 2024 | 2024-03-31 | $96.0M | −$15.1M | −13.57% |
| Q4 2023 | 2023-12-31 | $75.2M | $743,000 | +1.00% |
| Q3 2023 | 2023-09-30 | $87.1M | $1.3M | +1.57% |
| Q2 2023 | 2023-06-30 | $97.0M | $5.7M | +6.27% |
| Q1 2023 | 2023-03-31 | $111.1M | $5.3M | +4.99% |
| Q4 2022 | 2022-12-31 | $74.5M | −$45.4M | −37.85% |
| Q3 2022 | 2022-09-30 | $85.8M | −$48.0M | −35.89% |
| Q2 2022 | 2022-06-30 | $91.3M | −$54.2M | −37.25% |
| Q1 2022 | 2022-03-31 | $105.8M | −$32.6M | −23.58% |
| Q4 2021 | 2021-12-31 | $119.8M | −$30.1M | −20.09% |
| Q3 2021 | 2021-09-30 | $133.8M | $25.0M | +22.96% |
| Q2 2021 | 2021-06-30 | $145.5M | $52.4M | +56.21% |
| Q1 2021 | 2021-03-31 | $138.4M | $33.3M | +31.65% |
| Q4 2020 | 2020-12-31 | $150.0M | $26.5M | +21.51% |
| Q3 2020 | 2020-09-30 | $108.8M | −$33.1M | −23.32% |
| Q2 2020 | 2020-06-30 | $93.1M | −$58.7M | −38.66% |
| Q1 2020 | 2020-03-31 | $105.2M | $27.6M | +35.53% |
| Q4 2019 | 2019-12-31 | $123.4M | $35.3M | +40.13% |
| Q3 2019 | 2019-09-30 | $141.9M | — | — |
| Q2 2019 | 2019-06-30 | $151.8M | — | — |
| Q1 2019 | 2019-03-31 | $77.6M | — | — |
| Q4 2018 | 2018-12-31 | $88.1M | — | — |
Milestone Pharmaceuticals total assets trends
Over the last five fiscal years, Milestone Pharmaceuticals's total assets decreased from $150.0M to $113.6M, a change of −$36.4M. The latest reported quarter, Q2 2026, shows $181.6M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Milestone Pharmaceuticals source filings ↗